CBI Studies have already started for:

Coronavirus Treatments.

Coronavirus Treatment Studies at CBI

CBI is responding to an outbreak of respiratory disease caused by a novel (new) coronavirus that was first detected in China and which has now been detected in 60 locations internationally, including in the United States. The virus has been named "SARS-CoV-2" and the disease it causes has been named "coronavirus disease 2019" (abbreviated "COVID-19").

We are already responding to researchers and our sponsor's requests to plan and design preclinical pharmacology, toxicology and safety studies to assess new and novel treatment and vaccines for COVID-19. We are ready to initiate these studies immediately and to help our clients advance their products with all possible speed.

This is an emerging, rapidly evolving situation and Comparative Biosciences, Inc. will provide updated information as it becomes available, in addition to updated guidance.

- CUSTOM CORONAVIRUS DISEASE STUDY UPON REQUEST -

NEED TO CONDUCT A STUDY?

Click here and check out our website. www.compbio.com

Comparative Biosciences Inc.

A translational approach to biomedical services

786 Lucerne Drive  .  Sunnyvale, CA 94085  .  Telephone 408-738-9260